Parkworth Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

Parkworth Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$316	Buy	+8	New	+$262	﹤0.01%	773

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parkworth Wealth Management's IONS Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2025: 8 shares worth $316. The stake represents ﹤0.01% of the portfolio and ranks #773 among its holdings.

362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Parkworth Wealth Management held 8 shares of Ionis Pharmaceuticals worth $316 as of Q2 2025.
Ionis Pharmaceuticals was a new Parkworth Wealth Management position in Q2 2025.
Ionis Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #773 holding.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.